Sucampo Pharmaceuticals (NASDAQ:SCMP) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research note issued on Monday, Analyst Ratings Network reports. They currently have a $6.30 price objective on the stock. Zacks‘ price target would indicate a potential downside of 4.83% from the company’s current price.
SCMP has been the subject of a number of other recent research reports. Analysts at Credit Suisse initiated coverage on shares of Sucampo Pharmaceuticals in a research note to investors on Friday, June 21st. They set a “neutral” rating and a $8.00 price target on the stock. Separately, analysts at Cantor Fitzgerald raised their price target on shares of Sucampo Pharmaceuticals from $10.00 to $11.00 in a research note to investors on Thursday, May 9th. Finally, analysts at TheStreet downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note to investors on Thursday, May 9th.
One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $10.26.
Sucampo Pharmaceuticals (NASDAQ: SCMP) traded up 0.15% on Monday, hitting $6.63. Sucampo Pharmaceuticals has a 52-week low of $3.78 and a 52-week high of $10.48. The stock’s 50-day moving average is currently $6.9. The company has a market cap of $274.7 million and a price-to-earnings ratio of 76.09.
Sucampo Pharmaceuticals, Inc is a pharmaceutical Company. The Company is focused on the discovery, development and commercialization of drugs based on prostones.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.